These new insights into COVID-19 progression may be useful for a better understanding of the differences in the clinical symptoms after SARS-CoV-2 infection, and the identified serum cytokine panel, including IL6, IL1β, IL10, CXCL10, IGF1, and GALECTIN-1, may represent a selective targets to improve clinical therapeutic effects. Here, CXCL10 is linked to COVID-19.